Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of University of Science and Technology of China